Roth Capital Analysts Increase Earnings Estimates for BRTX

BioRestorative Therapies, Inc. (NASDAQ:BRTX) – Equities researchers at Roth Capital upped their FY2024 EPS estimates for BioRestorative Therapies in a report issued on Thursday, November 14th. Roth Capital analyst J. Aschoff now anticipates that the company will post earnings per share of ($1.43) for the year, up from their prior estimate of ($1.76). The consensus estimate for BioRestorative Therapies’ current full-year earnings is ($1.43) per share. Roth Capital also issued estimates for BioRestorative Therapies’ Q4 2024 earnings at ($0.27) EPS, Q1 2025 earnings at ($0.26) EPS, Q2 2025 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.86) EPS, FY2026 earnings at ($0.83) EPS and FY2027 earnings at $3.43 EPS.

BioRestorative Therapies (NASDAQ:BRTX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.22. BioRestorative Therapies had a negative return on equity of 98.49% and a negative net margin of 2,697.08%. The business had revenue of $0.23 million during the quarter, compared to the consensus estimate of $0.30 million.

Separately, Roth Mkm upped their price target on shares of BioRestorative Therapies from $15.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday, August 14th.

BioRestorative Therapies Price Performance

NASDAQ BRTX opened at $1.39 on Monday. The company has a market cap of $9.62 million, a P/E ratio of -0.86 and a beta of 63.40. BioRestorative Therapies has a 12 month low of $1.03 and a 12 month high of $3.67. The company has a 50-day moving average of $1.63 and a 200-day moving average of $1.60.

BioRestorative Therapies Company Profile

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.